Enfusion, Inc. (NYSE:ENFN) Stock Holdings Increased by Barclays PLC

Barclays PLC boosted its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 251.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,039 shares of the company’s stock after purchasing an additional 61,554 shares during the period. Barclays PLC owned approximately 0.07% of Enfusion worth $817,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Scalar Gauge Management LLC increased its stake in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after buying an additional 61,032 shares during the period. Renaissance Technologies LLC increased its position in shares of Enfusion by 167.6% in the second quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock worth $827,000 after acquiring an additional 60,811 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Enfusion during the third quarter valued at approximately $867,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Enfusion in the 2nd quarter valued at approximately $683,000. 81.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bradley Herring sold 24,443 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,918 shares of company stock valued at $484,037 in the last 90 days. 36.44% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on ENFN. Piper Sandler raised their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.25.

Enfusion Stock Performance

NYSE ENFN opened at $10.30 on Wednesday. The firm has a 50-day simple moving average of $9.92 and a 200 day simple moving average of $9.10. The stock has a market cap of $1.32 billion, a PE ratio of 257.56, a PEG ratio of 3.98 and a beta of 0.97. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.38.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.